Last reviewed · How we verify
TMX-67
At a glance
| Generic name | TMX-67 |
|---|---|
| Sponsor | SK Chemicals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES) (PHASE3)
- Effect of Febuxostat on Blood Pressure (PHASE2)
- Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout (PHASE2)
- Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina (PHASE2)
- Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment (PHASE2)
- Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones (PHASE2)
- Clinical Study to Evaluate the Pharmacokinetic Characteristics Between TMX-67 and Feburic® in Healthy Volunteers (PHASE1)
- Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TMX-67 CI brief — competitive landscape report
- TMX-67 updates RSS · CI watch RSS
- SK Chemicals Co., Ltd. portfolio CI